{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:09:12Z","timestamp":1789153752497,"version":"build-2803163510"},"reference-count":69,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2009.0549","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:12:39Z","timestamp":1525237959000},"source":"Crossref","is-referenced-by-count":14,"title":["Gout"],"prefix":"10.3238","author":[{"given":"Anne-Kathrin","family":"Tausche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim L.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Egbert","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan R.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2009,8,24]]},"reference":[{"key":"10.3238\/arztebl.2009.0549_ref1","doi-asserted-by":"crossref","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG: Gout epidemiology: results from the UK General Practice Research Database, 1990\u20131999. Ann Rheum Dis 2005; 64: 267\u201372.","DOI":"10.1136\/ard.2004.024091"},{"key":"10.3238\/arztebl.2009.0549_ref2","doi-asserted-by":"crossref","unstructured":"Annemans L, Spaepen E, Gaskin M, et al.: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005. Ann Rheum Dis 2008; 67: 960\u20136.","DOI":"10.1136\/ard.2007.076232"},{"key":"10.3238\/arztebl.2009.0549_ref3","doi-asserted-by":"crossref","unstructured":"Campion EW, Glynn RJ, DeLabry LO: Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987; 82: 421\u20136.","DOI":"10.1016\/0002-9343(87)90441-4"},{"key":"10.3238\/arztebl.2009.0549_ref4","doi-asserted-by":"crossref","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093\u2013103.","DOI":"10.1056\/NEJMoa035700"},{"key":"10.3238\/arztebl.2009.0549_ref5","doi-asserted-by":"crossref","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277\u201381.","DOI":"10.1016\/S0140-6736(04)16000-5"},{"key":"10.3238\/arztebl.2009.0549_ref6","doi-asserted-by":"crossref","unstructured":"Alamanos Y, Voulgari PV, Drosos AA : Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006; 36: 182\u20138.","DOI":"10.1016\/j.semarthrit.2006.08.006"},{"key":"10.3238\/arztebl.2009.0549_ref7","doi-asserted-by":"crossref","unstructured":"Tausche AK, Unger S, Richter K, et al.: Hyperuricemia and gout: diagnosis and therapy. Internist (Berl) 2006; 47: 509\u201322.","DOI":"10.1007\/s00108-006-1578-y"},{"key":"10.3238\/arztebl.2009.0549_ref8","doi-asserted-by":"crossref","unstructured":"Zhang W, Doherty M, Pascual E et al.: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301\u201311.","DOI":"10.1136\/ard.2006.055251"},{"key":"10.3238\/arztebl.2009.0549_ref9","doi-asserted-by":"crossref","unstructured":"Zhang W, Doherty M, Bardin T et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312\u201324.","DOI":"10.1136\/ard.2006.055269"},{"key":"10.3238\/arztebl.2009.0549_ref10","doi-asserted-by":"crossref","unstructured":"Unger S, Tausche AK, Kopprasch S, Bornstein SR, Aringer M, Gr\u00e4ssler J: Molecular basis of primary renal hyperuricemia: role of the human urate transporter hURAT1. Z Rheumatol 2007; 66: 58\u201361.","DOI":"10.1007\/s00393-007-0208-y"},{"key":"10.3238\/arztebl.2009.0549_ref11","doi-asserted-by":"crossref","unstructured":"Graessler J, Graessler A, Unger S et al.: Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006; 54: 292\u2013300.","DOI":"10.1002\/art.21499"},{"key":"10.3238\/arztebl.2009.0549_ref12","doi-asserted-by":"crossref","unstructured":"Graessler J, Unger S, Tausche AK, Kopprasch S, Bornstein SR: Gout \u2013 new insights into a forgotten disease. Horm Metab Res 2006; 38: 203\u20134.","DOI":"10.1055\/s-2006-925203"},{"key":"10.3238\/arztebl.2009.0549_ref13","doi-asserted-by":"crossref","unstructured":"Choi HK, Mount DB, Reginato AM: American College of Physicians; American Physiological Society: Pathogenesis of gout. Ann Intern Med 2005; 143: 499\u2013516.","DOI":"10.7326\/0003-4819-143-7-200510040-00009"},{"key":"10.3238\/arztebl.2009.0549_ref14","unstructured":"Harris MD, Siegel LB, Alloway JA: Gout and hyperuricemia. Am Fam Physician 1999; 59: 925\u201334."},{"key":"10.3238\/arztebl.2009.0549_ref15","unstructured":"Urano W, Yamanaka H, Tsutani H et al.: The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002; 29: 1950\u20133."},{"key":"10.3238\/arztebl.2009.0549_ref16","unstructured":"Wortmann RL: The management of gout: it should be crystal clear. J Rheumatol 2006; 33: 1921."},{"key":"10.3238\/arztebl.2009.0549_ref17","doi-asserted-by":"crossref","unstructured":"McGill NW: Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 445\u201360.","DOI":"10.1053\/berh.2000.0087"},{"key":"10.3238\/arztebl.2009.0549_ref18","unstructured":"Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31: 2429\u201332."},{"key":"10.3238\/arztebl.2009.0549_ref19","doi-asserted-by":"crossref","unstructured":"Jordan KM, Cameron JS, Snaith M et al.: British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG): British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1372\u20134.","DOI":"10.1093\/rheumatology\/kem056a"},{"key":"10.3238\/arztebl.2009.0549_ref20","doi-asserted-by":"crossref","unstructured":"Lumbreras B, Pascual E, Frasquet J, Gonz\u00e1lez-Salinas J, Rodr\u00edguez E, Hern\u00e1ndez-Aguado I: Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann Rheum Dis 2005; 64: 612\u20135.","DOI":"10.1136\/ard.2004.027268"},{"key":"10.3238\/arztebl.2009.0549_ref21","doi-asserted-by":"crossref","unstructured":"Shekarriz B, Stoller ML: Uric acid nephrolithiasis: current concepts and controversies. J Urol. 2002;168: 1307\u201314.","DOI":"10.1097\/00005392-200210010-00003"},{"key":"10.3238\/arztebl.2009.0549_ref22","doi-asserted-by":"crossref","unstructured":"Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC: The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 2003; 64: 1022\u20136.","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x"},{"key":"10.3238\/arztebl.2009.0549_ref23","doi-asserted-by":"crossref","unstructured":"Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47\u201356.","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"10.3238\/arztebl.2009.0549_ref24","doi-asserted-by":"crossref","unstructured":"Tausche AK, Aringer M, Schroeder HE, Bornstein SR, Wunderlich C, Wozel G: The janus faces of allopurinol \u2013 allopurinol hypersensitivity syndrome. Am J Med 2008; 121: e3\u20134.","DOI":"10.1016\/j.amjmed.2007.10.028"},{"key":"10.3238\/arztebl.2009.0549_ref25","doi-asserted-by":"crossref","unstructured":"Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM: Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 2006; 55: 786\u201390.","DOI":"10.1002\/art.22232"},{"key":"10.3238\/arztebl.2009.0549_ref26","doi-asserted-by":"crossref","unstructured":"Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811\u201321.","DOI":"10.1056\/NEJMra0800885"},{"key":"10.3238\/arztebl.2009.0549_ref27","doi-asserted-by":"crossref","unstructured":"Brand FN, McGee DL, Kannel WB, Stokes J 3rd, Castelli WP: Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121: 11\u20138.","DOI":"10.1093\/oxfordjournals.aje.a113972"},{"key":"10.3238\/arztebl.2009.0549_ref28","unstructured":"Julius U, Schulze J, Hanefeld M: \u00c4tiologie und Pathogenese des Metabolischen Syndroms. Diabetes und Stoffwechsel 2005; 14: 333\u201349."},{"key":"10.3238\/arztebl.2009.0549_ref29","unstructured":"Schr\u00f6der HE: Gicht. In: Hartmann F, Philipp T (Hrsg.): Klinik der Gegenwart. M\u00fcnchen, Wien, Baltimore: Urban und Schwarzenberg 1993; 1\u201348."},{"key":"10.3238\/arztebl.2009.0549_ref30","doi-asserted-by":"crossref","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582\u20137.","DOI":"10.1097\/01.rhu.0000147049.12220.32"},{"key":"10.3238\/arztebl.2009.0549_ref31","doi-asserted-by":"crossref","unstructured":"Weaver AL: Epidemiology of gout. Cleve Clin J Med 2008; 75: 9\u201312.","DOI":"10.3949\/ccjm.75.Suppl_5.S9"},{"key":"10.3238\/arztebl.2009.0549_ref32","doi-asserted-by":"crossref","unstructured":"Saag KG, Choi H: Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006; 8: 2.","DOI":"10.1186\/ar1907"},{"key":"10.3238\/arztebl.2009.0549_ref33","doi-asserted-by":"crossref","unstructured":"Vitart V, Rudan I, Hayward C et al.: SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437\u201342.","DOI":"10.1038\/ng.106"},{"key":"10.3238\/arztebl.2009.0549_ref34","doi-asserted-by":"crossref","unstructured":"Aringer M, Graessler J: Understanding deficient elimination of uric acid. Lancet 2008; 372: 1929\u201330.","DOI":"10.1016\/S0140-6736(08)61344-6"},{"key":"10.3238\/arztebl.2009.0549_ref35","doi-asserted-by":"crossref","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237\u201341.","DOI":"10.1038\/nature04516"},{"key":"10.3238\/arztebl.2009.0549_ref36","doi-asserted-by":"crossref","unstructured":"P\u00e9trilli V, Dostert C, Muruve DA, Tschopp J: The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19: 615\u201322.","DOI":"10.1016\/j.coi.2007.09.002"},{"key":"10.3238\/arztebl.2009.0549_ref37","doi-asserted-by":"crossref","unstructured":"Dalbeth N, Haskard DO: Inflammation and tissue damage in crystal deposition diseases. Curr Opin Rheumatol 2005; 17: 314\u20138.","DOI":"10.1097\/01.bor.0000157041.12116.69"},{"key":"10.3238\/arztebl.2009.0549_ref38","doi-asserted-by":"crossref","unstructured":"Rose DM, Liu-Bryan R: Innate immunity in triggering and resolution of acute gouty inflammation. Curr Rheumatol Rep 2006; 8: 209\u201314.","DOI":"10.1007\/s11926-996-0027-1"},{"key":"10.3238\/arztebl.2009.0549_ref39","doi-asserted-by":"crossref","unstructured":"Bellamy N, Downie WW, Buchanan WW: Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol 1987; 24: 33\u20136.","DOI":"10.1111\/j.1365-2125.1987.tb03132.x"},{"key":"10.3238\/arztebl.2009.0549_ref40","doi-asserted-by":"crossref","unstructured":"Smyth CJ: Disorders associated with hyperuricemia. Arthritis Rheum 1975; 18: 713\u20139.","DOI":"10.1002\/art.1780180712"},{"key":"10.3238\/arztebl.2009.0549_ref41","doi-asserted-by":"crossref","unstructured":"Schueller-Weidekamm C, Schueller G, Aringer M, Weber M, Kainberger F: Impact of sonography in gouty arthritis: Comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol 2007; 62: 437\u2013442.","DOI":"10.1016\/j.ejrad.2006.12.005"},{"key":"10.3238\/arztebl.2009.0549_ref42","doi-asserted-by":"crossref","unstructured":"Puig JG, de Miguel E, Castillo MC, Rocha AL, Mart\u00ednez MA, Torres RJ: Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008; 27: 592\u20135.","DOI":"10.1080\/15257770802136040"},{"key":"10.3238\/arztebl.2009.0549_ref43","doi-asserted-by":"crossref","unstructured":"Loebl WY, Scott JT: Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974; 33: 304\u20137.","DOI":"10.1136\/ard.33.4.304"},{"key":"10.3238\/arztebl.2009.0549_ref44","unstructured":"Li-Yu J, Clayburne G, Sieck M et al.: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577\u201380."},{"key":"10.3238\/arztebl.2009.0549_ref45","doi-asserted-by":"crossref","unstructured":"Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004 Jun 15;51(3):321-5.","DOI":"10.1002\/art.20405"},{"key":"10.3238\/arztebl.2009.0549_ref46","doi-asserted-by":"crossref","unstructured":"Rubin BR, Burton R, Navarra S, et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598\u2013606.","DOI":"10.1002\/art.20007"},{"key":"10.3238\/arztebl.2009.0549_ref47","doi-asserted-by":"crossref","unstructured":"Scheiman JM: Prevention of NSAID-induced ulcers. Curr Treat Options Gastroenterol 2008; 11: 125\u201334.","DOI":"10.1007\/s11938-008-0025-7"},{"key":"10.3238\/arztebl.2009.0549_ref48","doi-asserted-by":"crossref","unstructured":"Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M: Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17: 301\u20134.","DOI":"10.1111\/j.1445-5994.1987.tb01232.x"},{"key":"10.3238\/arztebl.2009.0549_ref49","doi-asserted-by":"crossref","unstructured":"Nuki G: Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008; 10: 218\u201327.","DOI":"10.1007\/s11926-008-0036-3"},{"key":"10.3238\/arztebl.2009.0549_ref50","doi-asserted-by":"crossref","unstructured":"Sutaria S, Katbamna R, Underwood M: Effectiveness of interventions for the treatment of acute and prevention of recurrent gout\u2014a systematic review. Rheumatology (Oxford) 2006; 45: 1422\u201331.","DOI":"10.1093\/rheumatology\/kel071"},{"key":"10.3238\/arztebl.2009.0549_ref51","doi-asserted-by":"crossref","unstructured":"Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371: 1854\u201360.","DOI":"10.1016\/S0140-6736(08)60799-0"},{"key":"10.3238\/arztebl.2009.0549_ref52","doi-asserted-by":"crossref","unstructured":"Williams PT: Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr 2008 May;87(5):1480-7.","DOI":"10.1093\/ajcn\/87.5.1480"},{"key":"10.3238\/arztebl.2009.0549_ref53","doi-asserted-by":"crossref","unstructured":"Gibson T, Rodgers V, Potter C, Simmonds HA: Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982; 41: 59\u201365.","DOI":"10.1136\/ard.41.1.59"},{"key":"10.3238\/arztebl.2009.0549_ref54","unstructured":"Ferraz MB, O'Brien B: A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995; 22: 908\u201314."},{"key":"10.3238\/arztebl.2009.0549_ref55","doi-asserted-by":"crossref","unstructured":"Delbarre F, Amor B, Auscher C, de Gery A: Treatment of gout with allopurinol. A study of 106 cases. Ann Rheum Dis 1966; 25: 627\u201333.","DOI":"10.1136\/ard.25.Suppl_6.627"},{"key":"10.3238\/arztebl.2009.0549_ref56","doi-asserted-by":"crossref","unstructured":"Yu TF: The effect of allopurinol in primary and secondary gout. Arthritis Rheum 1965; 8: 905\u20136.","DOI":"10.1002\/art.1780080456"},{"key":"10.3238\/arztebl.2009.0549_ref57","doi-asserted-by":"crossref","unstructured":"Lupton GP, Odom RB: The allopurinol hypersensitivity syndrome. Am Acad Dermatol 1979; 1: 365\u2013374.","DOI":"10.1016\/S0190-9622(79)70031-4"},{"key":"10.3238\/arztebl.2009.0549_ref58","doi-asserted-by":"crossref","unstructured":"Singer JZ, Wallace SL: The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82\u201387.","DOI":"10.1002\/art.1780290111"},{"key":"10.3238\/arztebl.2009.0549_ref59","unstructured":"Lee HY, Ariyasinghe JT, Thirumoorthy T: Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008; 49: 384\u20137."},{"key":"10.3238\/arztebl.2009.0549_ref60","doi-asserted-by":"crossref","unstructured":"Pak CY, Sakhaee K, Fuller C: Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986; 30: 422\u20138.","DOI":"10.1038\/ki.1986.201"},{"key":"10.3238\/arztebl.2009.0549_ref61","doi-asserted-by":"crossref","unstructured":"Reinders MK, van Roon EN, Jansen TL et al.: Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009; 68: 51\u20136.","DOI":"10.1136\/ard.2007.083071"},{"key":"10.3238\/arztebl.2009.0549_ref62","doi-asserted-by":"crossref","unstructured":"Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R: Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974; 17: 609\u201314.","DOI":"10.1002\/art.1780170517"},{"key":"10.3238\/arztebl.2009.0549_ref63","doi-asserted-by":"crossref","unstructured":"Pascual E, Sivera F: Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056\u20138.","DOI":"10.1136\/ard.2006.060368"},{"key":"10.3238\/arztebl.2009.0549_ref64","doi-asserted-by":"crossref","unstructured":"Gast LF: Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol 1987; 6: 70\u20133.","DOI":"10.1007\/BF02201004"},{"key":"10.3238\/arztebl.2009.0549_ref65","unstructured":"Lieshout-Zuidema MF, Breedveld FC: Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993; 20: 1383\u20135."},{"key":"10.3238\/arztebl.2009.0549_ref66","doi-asserted-by":"crossref","unstructured":"Becker MA, Schumacher HR, Wortmann RL et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450\u201361.","DOI":"10.1056\/NEJMoa050373"},{"key":"10.3238\/arztebl.2009.0549_ref67","doi-asserted-by":"crossref","unstructured":"Hair PI, McCormack PL, Keating GM: Febuxostat. Drugs 2008; 68: 1865\u201374.","DOI":"10.2165\/00003495-200868130-00006"},{"key":"10.3238\/arztebl.2009.0549_ref68","doi-asserted-by":"crossref","unstructured":"Fels E, Sundy JS: Refractory gout: what is it and what to do about it? Curr Opin Rheumatol 2008; 20: 198\u2013202.","DOI":"10.1097\/BOR.0b013e3282f4eff5"},{"key":"10.3238\/arztebl.2009.0549_ref69","doi-asserted-by":"crossref","unstructured":"Sundy JS, Becker MA, Baraf HS, et al.: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum 2008; 58: 2882\u201391.","DOI":"10.1002\/art.23810"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T04:40:48Z","timestamp":1638852048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,24]]},"references-count":69,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2009.0549","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1155\/2011\/397646","asserted-by":"object"},{"id-type":"doi","id":"10.3389\/fphar.2018.00261","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,24]]}}}